All News

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Prescription labels have a lot of details on them, which can make it difficult for patients to find and use important information.

Col. Dallas Hack, director of medical affairs at MagicMed, discusses the drug development program of a novel derivative of psilocybin for the treatment of post-traumatic stress disorder.

Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.

Additionally, among this population, combining aerobic exercise with a moderate reduction in daily calories resulted in greater improvements in aortic stiffness versus exercise only or exercise plus a more restrictive diet.

Vitamin K works against warfarin and can be used as an antagonist for it.

Median disease-free survival was nearly twice as long among patients with urothelial carcinoma who received nivolumab compared with placebo.

Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.

STRO-002 is a folate receptor alpha-targeting antibody drug conjugate for the treatment of patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior lines of systemic therapy.

The agents that have been evaluated and approved, and those that are coming in the pipeline, make for an exciting time to consider directed therapies.

This week’s recommendation by the Biden administration for booster shots to combat COVID-19 is a call to action for pharmacists to get ready for the upcoming flurry of activity.

Expanding services and revenues for pharmacies while improving public health and reducing stress on parents and others in the health care system is a win-win-win situation.

The study results indicated a nearly 9-fold increase in likelihood of survival without ventilation (SWOV) among this population, compared to a 2.5-fold increased likelihood of SWOV in the overall population.

The investigators concluded that a definite statement on risk or management recommendations cannot be made based on currently published data.

The pharmaceutical market is massive, clocking in at more than $1.2 trillion in 2020, with an anticipated growth of nearly $22 billion dollars expected in 2021. Examining which drug makes up the most of that revenue, one name pulls far away from the competition.

Study indicates that the genetics affecting aggression in children with attention-deficit hyperactivity disorder and disruptive behavior disorders are the same as genetics underlying aggression in the general population.

But state-to-state communications and inconsistencies related to licensing present legal issues.

The lower the glomerular filtration rate, the lower the stage, the worse kidney disease is.

As health care costs rise and cost-sharing increases, treatment-associated expenses will continue to burden patients.

Whereas traditional vaccines have used live or inactivated pathogens to elicit an immune response, mRNA is responsible for cellular processes, building structures, and more.

How would you answer these patients' questions?

The investigators analyzed a panel of antibodies generated in response to the Pfizer COVID-19 vaccine and found that delta was unable to evade all but 1 of the antibodies tested.

In clinical trials, empagliflozin significantly reduced the relative risk of the primary composite endpoint of time to cardiovascular death or hospitalization for heart failure by 25%.

CMS reported that 3.3 million more Medicare Part D beneficiaries with complex health needs than expected between 2013-2018 received a comprehensive medication review as a part of medication therapy management

In the sixth part of the series, students discussed how their involvement in pandemic-related vaccinations or aid efforts affected how they viewed the field and their role in the field.

According to the investigators, both trials demonstrated an overall well-tolerated safety profile for brolucizumab.

Specialty pharmacists’ roles have grown in new and exciting ways in recent years, and those changes have directly impacted health outcomes for all specialty patients, including patients with HIV.